
NBC News @NBCNews
The news last week that drugmaker Eli Lilly will cap out-of-pocket costs for its insulin at $35 per month brought relief to some. But what remains are systemic problems with insurance coverage and misdiagnosis that continue to challenge many with diabetes. https://t.co/4oIA83Kjz7 — PolitiTweet.org